T3 announces Abatacept Research Program supported by Bristol-Myers Squibb

Nidus physicians at Arthritis Northwest PLLC who are using the T3 JointMan® system have secured a grant from Bristol-Myers Squibb to conduct a retrospective Non-Interventional investigator Sponsored Trial (NIR ISR) focusing on comparative effectiveness. The study is designed to assess the effectiveness of Abatacept in patients being treated in “real world” clinical practice by analyzing the change in CDAI, DAS28, and RAPID3 scores between baseline and 3, 6, and 9 months of Abatacept administration. The study has Institutional Review Board (IRB) approval and is now commencing medical record review. It is anticipated that the results of the study will assist doctors and patients in medication selection by identifying which patient sub-groups are optimal responders.

With over 350,000 joints assessed in 11,000 de-identified patient records in the T3 data collaborative JointMan system, T3 is setting the standard for evidence-based medicine. T3 is a rheumatologist founded data collaborative for rheumatologists to protect and take advantage of their own data.

Read More